Bright Health Group Full Year 2022 Earnings: Misses Expectations

Simply Wall St

March 20, 2023

Bright Health Group (NYSE:BHG) Full Year 2022 Results

Key Financial Results

Revenue: US$2.41b (up 59% from FY 2021).
Net loss: US$773.3m (loss widened by 135% from FY 2021).
US$1.23 loss per share (further deteriorated from US$0.84 loss in FY 2021).

earnings-and-revenue-growth — NYSE:BHG Earnings and Revenue Growth March 20th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Bright Health Group Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 64%. Earnings per share (EPS) also missed analyst estimates by 43%.

Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Insurance industry in the US.

Performance of the American Insurance industry.

The company's shares are down 28% from a week ago.

Risk Analysis

Be aware that Bright Health Group is showing 3 warning signs in our investment analysis and 1 of those shouldn't be ignored...

If you're looking to trade NeueHealth, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Valuation is complex, but we're here to simplify it.

Discover if NeueHealth might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.